secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001558370-22-004208
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA reports FY2021 net loss of $75.7M; pro-forma cash $156.9M extends runway to H1 2024
--------------------------------------------------------------------------------

- Net loss widened to $75.7M in FY2021 from $44.1M in FY2020; R&D expenses rose to $82.9M.
- Pro-forma cash of $156.9M (Dec 31, 2021) reflects $35M Gilead equity, $15M fee, and $70M follow-on proceeds.
- Gilead HIV program advanced, triggering $54M commitment; $4M milestone, $15M fee, $35M equity at premium.
- HB-200 Phase 2 combo with pembrolizumab in HNSCC dosed Jan 2022; initial data expected H2 2022.
- Klaus Orlinger promoted to CSO; executive team accepted 50% of 2021 bonus in options at $3/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/0001558370-22-004208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022004208/hook-20220324x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-004208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer